Glad To See Covaxin Get Emergency Use Approval: WHO Chief


Covaxin was found to have 78% efficacy against COVID-19 of any severity, WHO said. (File)

United Nations/Geneva:

World Health Organisation Director-General Tedros Adhanom Ghebreyesus on Wednesday said he is “glad” to see Covaxin get the Emergency Use Listing approval, as he underlined that the more products the world has to fight the coronavirus pandemic, the better it is.

The approval came after the Technical Advisory Group (TAG), an independent advisory committee of WHO recommended EUL status for Covaxin.

“Glad to see one more vaccine, #Covaxin, being granted @WHO emergency use listing. The more products we have to fight #COVID19, the better, but we must keep up the pressure to deliver VaccinEquity & prioritize access to vulnerable groups who are still waiting for their 1st dose,” Ghebreyesus said in a tweet.

India’s Permanent Representative to the United Nations in Geneva Indramani Pandey also hailed the WHO’s decision and thanked Dr Tedros.

“We thank @DrTedros, DG, WHO, and his Team for their contribution in grant of EUL to Covaxin, a step towards fulfillment of the shared goal of India and @WHO of early vaccination and vaccine equity,” Mr Pandey said in a tweet.

Following the EUL approval for Covaxin, manufactured by Bharat Biotech, WHO Chief Scientist Soumya Swaminathan also congratulated India on getting the approval for Covaxin.

“One more vaccine gets @WHO emergency use listing. Congratulations India @BharatBiotech @ICMRDELHI @MoHFW_INDIA for successful development of indigenous vaccine #Covaxin as well as for a massive vaccination program!,” she said.

Covaxin was found to have 78 per cent efficacy against COVID-19 of any severity, 14 or more days after the second dose, and is extremely suitable for low- and middle-income countries due to easy storage requirements, it said.

Prime Minister Narendra Modi met WHO Director General Ghebreyesus on the sidelines of the G20 summit in Rome recently.

Besides demonstrating 77.8 per cent effectiveness against symptomatic COVID-19, Covaxin has shown 65.2 per cent protection against the new Delta variant.

In June, the company said it concluded the final analysis of Covaxin efficacy from Phase 3 trials.

Bharat Biotech’s Covaxin and AstraZeneca and Oxford University’s Covishield are the two widely used vaccines in India.

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)

Source link


Please enter your comment!
Please enter your name here